U.S. scientists have developed an experimental vaccine against the deadly Marburg virus, which causes Ebola-like hemorrhagic fever. The results of the study by the National Institute of Allergy and Infectious Diseases were published in the journal Science Translational Medicine.
According to the experts, just one injection of the ChAd3-MARV vaccine can create protective immunity for seven days after vaccination. In addition, the vaccine under study protected non-human primates when they were exposed to the deadly Marburg virus. It consists of an adenoviral vector that expresses the Marburg virus glycoprotein (MARV).
The animals remained protected against the pathogen when exposed to the virus one year after vaccination. The researchers also detected antigen-specific antibodies in the primates' blood.
The creation of ChAd3-MARV is seen as an important step toward achieving several goals-a vaccine for regions at risk of Marburg disease outbreaks and developing protective measures in case the virus is used by bioterrorists.
Follow NEWS.am Medicine on Facebook and Twitter